GleamWall
中文EN

IKT Inhibikase Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1750149 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-45.1%
TTM EPS YoY-185.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-52.9%
ROA-49.2%
ROIC (approx.)-68.9%
Asset turnover—

Leverage & solvency

Liabilities / assets6.4%
Debt / equity0.00x
Current ratio15.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue—$0$0—$0$0$0$0
R&D expense$15.00M$13.39M$10.84M$6.36M$7.65M$5.27M$10.51M$7.19M
SG&A expense$7.23M$7.66M$7.38M$6.77M$5.61M$5.92M$5.25M$5.74M
Operating income-$22.23M-$21.05M-$17.84M-$13.78M-$12.77M-$10.83M-$14.60M-$12.93M
Income tax—$0$0$0$0$0$0$0
Net income-$20.47M-$19.59M-$16.38M-$12.73M-$11.93M-$9.92M-$13.68M-$12.13M
EBITDA-$22.23M-$21.05M-$17.84M-$13.78M-$12.74M-$10.81M-$14.59M-$12.92M
EPS (basic)-0.10-0.11-0.10—-0.13-0.11-0.15—
EPS (diluted)-0.10-0.11-0.10—-0.13-0.11-0.15—
Weighted avg. shares (diluted)196.94M174.57M172.31M—90.05M90.01M89.54M—
Banking
Net interest income$1.76M$1.46M$1.46M$1.04M$838,093$916,755$919,271$796,123
Balance sheet
Cash & equivalents$51.70M$31.21M$49.57M$139.22M$38.27M$77.74M$73.44M$56.49M
Short-term investments$141.62M$127.81M$120.80M$39.54M$39.05M$9.92M$19.74M$41.05M
Current assets$198.73M$162.34M$172.18M$180.11M$78.54M$88.79M$94.16M$98.45M
PP&E, net———$0$0$23,687$47,845$47,100
Total assets$201.75M$163.59M$173.33M$181.20M$79.59M$88.85M$94.28M$98.60M
Current liabilities$12.96M$10.26M$5.71M$8.30M$6.70M$8.80M$8.55M$3.73M
Short-term debt———$0$0$37,944$74,772$110,517
Total liabilities$12.96M$10.26M$5.71M$8.30M$6.70M$8.80M$8.55M$3.73M
Shareholders' equity$188.80M$153.33M$167.62M$172.90M$72.90M$80.05M$85.73M$94.87M
Shares outstanding140.27M132.03M132.03M131.69M74.81M74.52M74.34M69.36M
Cash flow statement
Operating cash flow-$17.35M-$12.44M-$12.06M-$7.52M-$10.59M-$5.57M-$4.10M-$5.35M
Capital expenditure$0$0$0$0$0$0$13,399$0
Free cash flow-$17.35M-$12.44M-$12.06M-$7.52M-$10.59M-$5.57M-$4.12M-$5.35M
Investing cash flow-$12.61M-$5.91M-$80.48M-$98,847-$28.75M$9.84M$21.05M-$38.76M
Financing cash flow$50.46M-$14,489$2.90M$108.57M-$134,130$31,771$0$99.68M
Depreciation & amortization$0$0$0$0$23,688$24,157$12,654$6,567
Stock-based compensation$5.53M$5.35M$5.56M$4.53M$4.53M$4.21M$2.04M$7.91M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.